#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

News

zaměnitelnost léků

Interchangeability of Diosmin and Micronized Purified Flavonoid Fraction

16. 9. 2022 Source: Venous Insufficiency

Among the medicinal products reimbursed for chronic venous disease, those containing micronized diosmin (Diozen 180 tbl.) have been newly included. Which substances are available for this indication, and what determined the interchangeability of micronized diosmin with micronized purified flavonoid fraction (MPFF) and other selected venotonics stabilizing capillaries?

sepse

Ceftaroline as a Treatment Option for MRSA-Induced Sepsis?

A recently published study by a team of authors from several American institutions focused on…
16. 9. 2022 Source: Anti-Infectives
Hladina TSH

Association of Low TSH Levels in Hypothyroidism Therapy with Mortality Risk

Community surveys indicate that up to 53% of patients treated for hypothyroidism have serum…
14. 9. 2022 Source: Thyroid Disorders
zkumavky laboratoř

Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism

The relationship between the level of antithyroid antibodies and the required dose of levothyroxine…
14. 9. 2022 Source: Thyroid Disorders
plaková psoriaza čelo

Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis

Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and…
12. 9. 2022 Source: Psoriasis
Spine cancer

How to Most Effectively Delay Skeletal Events in Patients with Bone Metastases from Solid Tumors?

In a randomized Phase III study, the effectiveness of denosumab and zoledronic acid in preventing…
12. 9. 2022 Source: Prevention of Bone Events
Doctor computer

Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer

In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the…
12. 9. 2022 Source: Prevention of Bone Events
doc. Debora Karetová

Doc. Debora Karetová: Do Not Underestimate the Complexity of CHVO Treatment and Early Stages of the Disease

Are you applying the optimal approach to the treatment of chronic venous disease? What do the new…
12. 9. 2022 Source: Venous Insufficiency
Výsledky klinické studie

Brigatinib in Patients with ALK+ NSCLC –⁠ Final Results of the J-ALTA Clinical Study

At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early…
12. 9. 2022 Source: Non-Small Cell Lung Cancer
rakovina plic

Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib

Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect…
12. 9. 2022 Source: Non-Small Cell Lung Cancer
1 65 66 67 68 69 168
Filter by speciality
Remove filters

Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#